Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 24;6(1):91.
doi: 10.1186/1758-5996-6-91. eCollection 2014.

The role of glucagon on type 2 diabetes at a glance

Amélio F Godoy-Matos  1
Affiliations
Review

The role of glucagon on type 2 diabetes at a glance

Amélio F Godoy-Matos. Diabetol Metab Syndr. .

Abstract

The opposite effects of insulin and glucagon in fuel homeostasis, the paracrine/endocrine inhibitory effects of insulin on glucagon secretion and the hyperglucagonemia in the pathogenesis of type 2 diabetes (T2D) have long been recognized. Inappropriately increased alpha-cell function importantly contributes to hyperglycemia and reflects the loss of tonic restraint normally exerted by high local concentrations of insulin on alpha-cells, possibly as a result of beta-cell failure and alpha-cell insulin resistance, but additional mechanisms, such as the participation of incretin hormones in this response, have also been suggested. Three classes of drugs already available for clinical use address the abnormalities of glucagon secretion in T2D, namely, the GLP-1 receptor agonists (GLP-1RA), the inhibitors of dipeptidyl peptidase-4 (DPP-4i) and the amylin agonist pramlintide; it has been proposed that the glucagonostatic and insulinotropic effects of GLP-1RA equally contribute to their hypoglycemic efficacy. In this review, the control of glucagon secretion and its participation in T2D pathogenesis are summarized.

Keywords: GLP-1; Hiperglucagonemia; Incretin effect; Type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Main contributors to hyperglycemia in Type 2 diabetes mellitus. AGE: advanced glycation endproducts.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Murlin JR, Clough HD, Gibbs CBF, Stokes AM. Aqueous extracts of the pancreas. 1. Influence on the carbohydrate metabolism of depancreatized animals. J Biol Chem. 1923;56:253–296.
    1. Sutherland EW, De Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem. 1948;175:663–674. - PubMed
    1. Unger RH, Eisentraut AM, Mc CM, Keller S, Lanz HC, Madison LL. Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med. 1959;102:621–623. doi: 10.3181/00379727-102-25338. - DOI - PubMed
    1. Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P. Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab. 2011;13(Suppl 1):95–105. doi: 10.1111/j.1463-1326.2011.01450.x. - DOI - PubMed
    1. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007;28:84–116. doi: 10.1210/er.2006-0007. - DOI - PubMed